XOMA (XOMA) Sinks as Phase 2b Trial of 052 Failed to Reach Endpoint
Tweet
Share
E-mailGet Alerts XOMA Hot Sheet
Join SI Premium – FREE
Shares of XOMA (Nasdaq: XOMA) are down 33% in after-hours trading Tuesday following news that the company's Phase 2b trial on 052 missed its primary endpoint.
Although 052's safety was confirmed, glucose control was not demonstrated and a reduction in glycosylated hemoglobin for Type 2 diabetes patients was not achieved.
XOMA shares last traded at $3.45. The stock is extremely active after-hours.
Although 052's safety was confirmed, glucose control was not demonstrated and a reduction in glycosylated hemoglobin for Type 2 diabetes patients was not achieved.
XOMA shares last traded at $3.45. The stock is extremely active after-hours.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Sigma Lithium resumes full operations after signing TAC agreement
- CoVolt Power files for proposed IPO
Create E-mail Alert Related Categories
Corporate News, FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
